Cognition at each stage of Lewy body disease with co-occurring Alzheimer’s disease pathology

Manuscript Number: 

20-1187R2

Author(s): 
Douglas Galasko, Victor W. Henderson, Thomas J. Montine, Kathleen L. Poston, Sephira G. Ryman, David P. Salmon, Lu Tian, Maya Yutsis

Disclosures

Douglas Galasko

  • Consulting Fees:
    Consultant for Biogen, Inc, Amprion, Inc, Fujirebio, Inc. DSMB for Cognition Therapeutics Paid Editor for Alzheimer's Research & Therapy
    Grants
    • Agency: 
      Eli Lilly, Inc
      Dates: 
      2015-2021
    • Agency: 
      Biogen, Inc
      Dates: 
      2018-2019

Victor W. Henderson

  • Nothing to Disclose

Thomas J. Montine

  • Nothing to Disclose

Kathleen L. Poston

  • Consulting Fees:
    Consulting fees from Curasen Therapeutics, Inc
    Equity:
    Stock options from Curasen Therapeutics, Inc

Sephira G. Ryman

  • Nothing to Disclose

David P. Salmon

  • Consulting Fees:
    Personal Fees from Biogen, Aptinyx, Inc.

Lu Tian

  • Nothing to Disclose

Maya Yutsis

  • Nothing to Disclose